DE69731658D1 - Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen - Google Patents
Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungenInfo
- Publication number
- DE69731658D1 DE69731658D1 DE69731658T DE69731658T DE69731658D1 DE 69731658 D1 DE69731658 D1 DE 69731658D1 DE 69731658 T DE69731658 T DE 69731658T DE 69731658 T DE69731658 T DE 69731658T DE 69731658 D1 DE69731658 D1 DE 69731658D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor antagonists
- motion disorders
- treating motion
- antagonist
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9625051 | 1996-12-02 | ||
GB9625051A GB9625051D0 (en) | 1996-12-02 | 1996-12-02 | Therapeutic agents |
GB9701459A GB9701459D0 (en) | 1997-01-24 | 1997-01-24 | Therapeutic agents |
GB9701459 | 1997-01-24 | ||
GB9713715 | 1997-06-27 | ||
GB9713715A GB9713715D0 (en) | 1997-06-27 | 1997-06-27 | Therapeutic agents |
GBGB9717425.4A GB9717425D0 (en) | 1997-08-15 | 1997-08-15 | Therapeutic use |
GB9717425 | 1997-08-15 | ||
GBGB9721193.2A GB9721193D0 (en) | 1997-10-07 | 1997-10-07 | Therapeutic use |
GB9721193 | 1997-10-07 | ||
PCT/EP1997/006692 WO1998024446A1 (en) | 1996-12-02 | 1997-11-25 | Use of nk-1 receptor antagonists for treating movement disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69731658D1 true DE69731658D1 (de) | 2004-12-23 |
DE69731658T2 DE69731658T2 (de) | 2005-12-01 |
Family
ID=27517390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69731658T Expired - Fee Related DE69731658T2 (de) | 1996-12-02 | 1997-11-25 | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen |
Country Status (9)
Country | Link |
---|---|
US (1) | US5925627A (de) |
EP (1) | EP0942732B1 (de) |
JP (1) | JP2001507678A (de) |
AT (1) | ATE282417T1 (de) |
AU (1) | AU734872B2 (de) |
CA (1) | CA2273809A1 (de) |
DE (1) | DE69731658T2 (de) |
ES (1) | ES2231902T3 (de) |
WO (1) | WO1998024446A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0991622A1 (de) * | 1997-06-27 | 2000-04-12 | MERCK SHARP & DOHME LTD. | Substituierte 3-(benzylamino)piperidin derivate und ihre verwendung als therapeutische wirkstoffe |
US6271230B1 (en) * | 1997-12-01 | 2001-08-07 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating cognitive disorders |
US6156749A (en) * | 1997-12-01 | 2000-12-05 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating movement disorders |
DE19830201A1 (de) * | 1998-07-07 | 2000-01-13 | Boehringer Ingelheim Pharma | Mittel mit antidepressiver Wirkung |
MXPA02005675A (es) | 1999-12-10 | 2002-09-02 | Pfizer Prod Inc | Compuestos de pirrolo(2,3-d)pirimidina. |
ES2267627T3 (es) | 2001-05-11 | 2007-03-16 | Jurgen K. Dr. Beck | Flibaserina para el tratamiento de los trastornos del movimiento estrapiramidal. |
AU2003278529A1 (en) | 2002-11-21 | 2004-06-15 | Pfizer Products Inc. | 3-amino-piperidine derivatives and processes for their preparation |
BRPI0807972A2 (pt) | 2007-01-24 | 2014-06-10 | Glaxo Group Ltd | Composições farmacêuticas compreendendo 3,5-diamino-6-(2,3-diclofenil)-l,2,4-triazina ou r(-)-2,4-diamino-5-(2,3-diclorofenil)-6-fluorometilpirim idina e uma nk1 |
EP3609495A4 (de) * | 2017-04-10 | 2020-12-02 | Chase Therapeutics Corporation | Nk1-antagonistenkombination und verfahren zur behandlung von synukleinopathien |
CA3121184A1 (en) * | 2018-09-25 | 2020-04-02 | Chase Therapeutics Corporation | Composition and use for the treatment of parkinson's disease and related disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX18467A (es) * | 1988-11-23 | 1993-07-01 | Pfizer | Agentes terapeuticos de quinuclidinas |
EP1082959A1 (de) * | 1991-09-20 | 2001-03-14 | Glaxo Group Limited | NK1 Antagonisten zur Behandlung von Depression |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
IL106142A (en) * | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
FR2700472B1 (fr) * | 1993-01-19 | 1995-02-17 | Rhone Poulenc Rorer Sa | Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2. |
US5496833A (en) * | 1993-04-13 | 1996-03-05 | Merck Sharp & Dohme Limited | Piperidine tachykinin receptor antagonists |
IL111002A (en) * | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
US5612337A (en) * | 1993-12-29 | 1997-03-18 | Merck Sharp & Dohme Limited | Substituted morpholine derivatives and their use as therapeutic agents |
TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5824678A (en) * | 1994-08-15 | 1998-10-20 | Merck Sharp & Dohme Ltd. | Morpholine derivatives and their use as therapeutic agents |
GB9426103D0 (en) * | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Therapeutic agents |
AU4918796A (en) * | 1995-02-10 | 1996-08-27 | Eli Lilly And Company | Methods of treating or preventing psychiatric disorders |
GB9505692D0 (en) * | 1995-03-21 | 1995-05-10 | Glaxo Group Ltd | Chemical compounds |
FR2755013B1 (fr) * | 1996-10-29 | 1998-11-27 | Rhone Poulenc Rorer Sa | Nouvelle application therapeutique des antagonistes de la substance p |
-
1997
- 1997-11-25 CA CA002273809A patent/CA2273809A1/en not_active Abandoned
- 1997-11-25 DE DE69731658T patent/DE69731658T2/de not_active Expired - Fee Related
- 1997-11-25 WO PCT/EP1997/006692 patent/WO1998024446A1/en active IP Right Grant
- 1997-11-25 AU AU55594/98A patent/AU734872B2/en not_active Ceased
- 1997-11-25 EP EP97952024A patent/EP0942732B1/de not_active Revoked
- 1997-11-25 JP JP52517798A patent/JP2001507678A/ja not_active Ceased
- 1997-11-25 ES ES97952024T patent/ES2231902T3/es not_active Expired - Lifetime
- 1997-11-25 AT AT97952024T patent/ATE282417T1/de not_active IP Right Cessation
- 1997-12-01 US US08/980,931 patent/US5925627A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0942732A1 (de) | 1999-09-22 |
WO1998024446A1 (en) | 1998-06-11 |
ATE282417T1 (de) | 2004-12-15 |
EP0942732B1 (de) | 2004-11-17 |
CA2273809A1 (en) | 1998-06-11 |
AU734872B2 (en) | 2001-06-21 |
ES2231902T3 (es) | 2005-05-16 |
DE69731658T2 (de) | 2005-12-01 |
AU5559498A (en) | 1998-06-29 |
JP2001507678A (ja) | 2001-06-12 |
US5925627A (en) | 1999-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
MX9706969A (es) | 3-(1,2,3,6-tetrahidropiridin-4-il)-1h-indoles y 3-(piperidin-4-il)-1h-indoles sustituidos en la posicion 5: agonistas del 5-ht1f novedosos. | |
ATE177095T1 (de) | Substituierte piperidine für die behandlung von allergischen krankheiten | |
DK0729468T3 (da) | Ikke-peptid tachykinin-receptor-antagonister | |
HK1008819A1 (en) | Piperidine derivatives as neurokinin antagonists | |
ATE267595T1 (de) | Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1- rezeptoren und sibutramine enthalten | |
NO983002L (no) | Vitronectin-reseptor-antagonister | |
NO944578L (no) | Eksitatoriske aminosyre reseptor antagonister | |
ATE304530T1 (de) | Substituierte 1,5-dihydropyrrol-2-on-derivate wirksam als nmda-rezeptor-antagonisten für die behandlung von schmerzzuständen | |
DE69731658D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von bewegungsstörungen | |
DK0989973T3 (da) | Chalconer med antiproliferativ aktivitet | |
ATE381533T1 (de) | Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung | |
DE69917230D1 (de) | Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält | |
FI973221A0 (fi) | 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina | |
ATE320832T1 (de) | Behandlung von haarfollikeln mit neurokinin 1 rezeptor antagonisten | |
DE69731657D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
DE69808475T2 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
ATE293975T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen | |
DE69732492D1 (de) | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden | |
DE69730515D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlungen von stress störungen | |
MX9703483A (es) | Antagonistas del receptor de nk-1 para el tratamiento de trastornos oculares. | |
NO981188D0 (no) | 5-HT3-reseptorantagonister for dyskinesi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent | ||
8339 | Ceased/non-payment of the annual fee |